Target Engagement | Acumen Pharmaceuticals

2024 ADPD Poster

May 31, 2024/in 2024 2024, ADPD, INTERCEPT-AD, Poster, Target Engagement, TwentyTwentyFour /by Robyn Moxon

2024 ADPD Poster:

Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug (ACU193)-Amyloid Βeta Oligomer Complexes in Human CSF.

2024 AAN Presentation

May 31, 2024/in 2024 2024, AAN, Biomarkers, INTERCEPT-AD, Presentation, Target Engagement, TwentyTwentyFour /by Robyn Moxon

2024 AAN Presentation:

A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.

2024 AAN Poster

May 31, 2024/in 2024 2024, AAN, Biomarkers, INTERCEPT-AD, Poster, Target Engagement, TwentyTwentyFour /by Robyn Moxon

2024 AAN Poster:

A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.

2023 CTAD Presentation

May 31, 2023/in 2023 2023, Amyloid Plaque, ARIA, CTAD, INTERCEPT-AD, Presentation, Target Engagement, TwentyTwentyThree /by Robyn Moxon

2023 CTAD Presentation:

INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers.

2023 CTAD Poster

May 31, 2023/in 2023 2023, CTAD, INTERCEPT-AD, Poster, Target Engagement, TwentyTwentyThree /by Robyn Moxon

2023 CTAD Poster:

ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay of Target Engagement for the sAβO-Selective Antibody ACU193 in INTERCEPT-AD.